Four Japanese Giants Team Up to Revolutionize Regenerative Medicine by 2030
Four prominent Japanese companies have joined forces to revolutionize regenerative medicine. Kuraray Co., Cyfuse Biomedical K.K., Chiyoda Corp., and Zacros Corp. have partnered to develop mass cultivation technology for stem cells, aiming to bring the practical use of 3D-printed tissues to the market.
The collaboration, set to conclude by 2030, will see the companies sharing resources and expertise. Zacros Corp. will provide cultivation equipment, while Kuraray Co. will offer substances to enhance cultivation efficiency. The shared knowledge will include analysis methods and safety verification techniques, crucial for commercial production.
The partnership's primary goal is to facilitate the mass cultivation of stem cells, a vital step in the commercial production of various tissues using 3D printers. Cyfuse Biomedical K.K.'s CEO, Shizuka Akieda, expressed the companies' collective aim to strengthen their technologies for commercial production, capitalizing on the expanding regenerative medicine market.
By 2030, the four Japanese companies aim to establish mass cultivation technology for stem cells, paving the way for the practical use of regenerative medicine. Their partnership, focused on sharing resources and expertise, is a significant step towards commercializing 3D-printed tissues and revolutionizing healthcare.
